Literature DB >> 17041638

Characterization of an artificial antigen-presenting cell to propagate cytolytic CD19-specific T cells.

T Numbenjapon, L M Serrano, H Singh, C M Kowolik, S Olivares, N Gonzalez, W C Chang, S J Forman, M C Jensen, L J N Cooper.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17041638     DOI： 10.1038/sj.leu.2404329

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  18 in total

Review 1.  Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials.

Authors:  D L DiGiusto; L J N Cooper
Journal:  Cytotherapy       Date:  2007       Impact factor: 5.414

Review 2.  Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor.

Authors:  H Singh; J S E Moyes; M H Huls; L J N Cooper
Journal:  Cancer Gene Ther       Date:  2015-01-16       Impact factor: 5.987

3.  Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor.

Authors:  Drew C Deniger; Kirsten Switzer; Tiejuan Mi; Sourindra Maiti; Lenka Hurton; Harjeet Singh; Helen Huls; Simon Olivares; Dean A Lee; Richard E Champlin; Laurence J N Cooper
Journal:  Mol Ther       Date:  2013-01-08       Impact factor: 11.454

Review 4.  Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.

Authors:  Bipulendu Jena; Gianpietro Dotti; Laurence J N Cooper
Journal:  Blood       Date:  2010-05-03       Impact factor: 22.113

5.  Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules.

Authors:  Megan M Suhoski; Tatiana N Golovina; Nicole A Aqui; Victoria C Tai; Angel Varela-Rohena; Michael C Milone; Richard G Carroll; James L Riley; Carl H June
Journal:  Mol Ther       Date:  2007-03-20       Impact factor: 11.454

6.  Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies.

Authors:  Jeff K Davies; Harjeet Singh; Helen Huls; Dongin Yuk; Dean A Lee; Partow Kebriaei; Richard E Champlin; Lee M Nadler; Eva C Guinan; Laurence J N Cooper
Journal:  Cancer Res       Date:  2010-04-27       Impact factor: 12.701

Review 7.  NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies.

Authors:  Edwin P Alyea; Daniel J DeAngelo; Jeffrey Moldrem; John M Pagel; Donna Przepiorka; Michel Sadelin; James W Young; Sergio Giralt; Michael Bishop; Stan Riddell
Journal:  Biol Blood Marrow Transplant       Date:  2010-05-24       Impact factor: 5.742

Review 8.  A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19.

Authors:  Harjeet Singh; Helen Huls; Partow Kebriaei; Laurence J N Cooper
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 9.  Human cell-based artificial antigen-presenting cells for cancer immunotherapy.

Authors:  Marcus O Butler; Naoto Hirano
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

10.  Bayesian continual reassessment method for dose-finding trials infusing T cells with limited sample size.

Authors:  Yuan Ji; Lei Feng; Ping Liu; Elizabeth J Shpall; Partow Kebriaei; Richard Champlin; Donald Berry; Laurence J N Cooper
Journal:  J Biopharm Stat       Date:  2012       Impact factor: 1.051
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.